SCHEMBL1865632

SCHEMBL1865632

CC1CCCCN1CCCC(=O)O

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 6/20 0.57
SCN1A P35498 2/20 0.53
SCN2A Q99250 2/20 0.53
SCN3A Q9NY46 2/20 0.53
CYP1A2 P05177 2/20 0.50
MAPK1 P28482 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CXCR4 P61073 6/20 0.47
LTA4H P09960 2/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
TSHR P16473 1/20 0.44
CYP2C19 P33261 1/20 0.44
TERT O14746 1/20 0.44
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1855290 1.00 HRH3 (0.57) HRH3SCN1ASCN2ASCN3ACYP1A2
Hydrochloric Acid SCHEMBL11334822 0.98 HRH3 (0.56) HRH3SCN1ASCN2ASCN3ACYP1A2
SCHEMBL11626844 0.95 HRH3 (0.56) HRH3SCN1ASCN2ASCN3ACYP1A2
SCHEMBL1861972 0.95 HRH3 (0.62) HRH3SCN1ASCN2ASCN3ACYP1A2
SCHEMBL1858200 0.95 HRH3 (0.62) HRH3SCN1ASCN2ASCN3ACYP1A2
SCHEMBL1856917 0.95 HRH3 (0.62) HRH3SCN1ASCN2ASCN3ACYP1A2
SCHEMBL27778773 0.93 HRH3 (0.54) HRH3SCN1ASCN2ASCN3ACYP1A2
SCHEMBL17598220 0.90 HRH3 (0.60) HRH3SCN1ASCN2ASCN3ACYP1A2
SCHEMBL499914 0.89 HRH3 (0.55) HRH3SCN1ASCN2ASCN3ACXCR4
SCHEMBL27894811 0.88 HRH3 (0.59) HRH3SCN1ASCN2ASCN3ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023196527-A2 IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS SunVax mRNA Therapeutics Inc. (US) 2023-10-12 WO disclosed
US-20230322689-A1 IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS SunVax mRNA Therapeutics Inc. (US) 2023-10-12 US disclosed
US-20230322689-A1 IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS SunVax mRNA Therapeutics Inc. (US) 2023-10-12 US disclosed
EP-2118067-B1 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS SIENA BIOTECH SPA (IT) 2013-05-08 EP disclosed
CN-101679287-B Nicotinic acetylcholine receptor modulators SIENA BIOTECH SPA 2013-03-27 CN disclosed
US-8163729-B2 Modulators of α7 nicotinic acetylcholine receptors and therapeutic uses thereof WYETH (US) 2012-04-24 US disclosed
EP-2323988-A1 ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS Wyeth LLC (US) 2011-05-25 EP disclosed
US-20100130474-A1 ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS WYETH (US) 2010-05-27 US disclosed
CN-101679287-A nicotinic acetylcholine receptor modulators SIENA BIOTECH SPA 2010-03-24 CN disclosed
US-20100029606-A1 MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF WYETH (US) 2010-02-04 US disclosed
US-4248874-A QUINUCLIDINE DERIVATIVES ABBOTT LABORATORIES (US) 1981-02-03 US disclosed
US-4247557-A Benzopyranopyridines as antiglaucoma agents ABBOTT LABORATORIES (US) 1981-01-27 US disclosed
US-4217351-A Benzopyrano quinuclidines useful as antiglaucoma agents ABBOTT LABORATORIES (US) 1980-08-12 US disclosed
US-4136183-A BENZOPYRANOPYRIDINES AS ANTIGLAUCOMA AGENTS ABBOTT LABORATORIES (US) 1979-01-23 US disclosed
US-4081449-A ANALGESICS, ANTICONVULSANTS ABBOTT LABORATORIES (US) 1978-03-28 US disclosed
US-4042694-A ANALGESICS SHARPS ASSOCIATES (US) 1977-08-16 US disclosed
US-4025630-A Anesthesia methods using benzopyrans and esters thereof as pre-anesthesia medication ABBOTT LABORATORIES (US) 1977-05-24 US disclosed
US-4020163-A Use of heterocyclic esters of 5H-[1]benzopyrano [3,4-b]pyridines as analgesics SHARPS ASSOCIATES (US) 1977-04-26 US disclosed
US-3991194-A Heterocyclic esters of benzopyranopyridines SHARPS ASSOCIATES (US) 1976-11-09 US disclosed
US-3941782-A Heterocyclic esters of benzopyrans SHARPS ASSOCIATES (US) 1976-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029606-A1 MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF CHRNA7, CHRNA2, CHRNA6 HRH3 493/4885SCN1A 332/4885SCN2A 421/4885
US-20100130474-A1 ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS CHRNA7, CHRNA6, CHRNA2 HRH3 384/4885SCN1A 350/4885SCN2A 453/4885
US-20230322689-A1 IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS PHOSPHO1, SGMS1, PLIN3 HRH3 3622/4885SCN1A 1902/4885SCN2A 2196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.